Novavax (NVAX)
(Delayed Data from NSDQ)
$3.97 USD
+0.08 (2.06%)
Updated Apr 19, 2024 03:59 PM ET
After-Market: $3.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
NVAX 3.97 +0.08(2.06%)
Will NVAX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NVAX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVAX
What's in Store for Biogen (BIIB) This Earnings Season?
J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?
NVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Other News for NVAX
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. stock remains steady Thursday, still outperforms market
Novavax Inc. stock underperforms Wednesday when compared to competitors
Novavax Inc. stock underperforms Tuesday when compared to competitors
Shah Capital calls for board shake-up at Novavax